Ticker: LLY

Eli Lilly

Pharma Healthcare Drug Manufacturers - General

Price 1127.14

Reco Hold Potential 60 Risk 70 Updated 2026-09-09

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.

Investment Profile

Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Long-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-09-06

EPS (TTM) — earnings per share for the last 12 months, $: 29.85
Revenue QoQ — quarter-over-quarter revenue growth: 16.0%
EPS surprise: 30.9%
20d volatility: 1.8%
Dividend yield: 0.6%
last ex-date: 2026-08-14

AI recommendation changes

Date	Before	After	Reason
2026-09-06	Buy	Hold	Mixed performance; cautious due to high risk factors.
2026-08-06	Hold	Buy	Strong fundamentals and positive momentum support growth outlook.
2026-07-31	Buy	Hold	Weak momentum and high risk; cautious approach advised.
2026-05-18	Hold	Buy	Strong fundamentals and positive short-term momentum.
2026-05-10	Buy	Hold	Weak momentum and high risk; mixed analyst signals.
2026-05-08	—	Buy	Solid fundamentals but mixed momentum signals.
2026-05-08	Buy	Buy	Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29	Hold	Buy	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17	Buy	Hold	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09	Hold	Buy	Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22	Buy	Hold	Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06	Hold	Buy	Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29	Buy	Hold	Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-08-07	UBS	Target Raised	1370 → 1376	1177.33
2026-08-06	Cantor Fitzgerald	Target Raised	1350 → 1410	1181
2026-08-06	Morgan Stanley	Target Raised	1347 → 1419	1169.86
2026-08-06	Wells Fargo	Target Raised	— → 1330	1169.86
2026-08-06	BMO Capital	Target Raised	— → 1400	1169.86
2026-07-14	Bernstein	Target Raised	— → 1385	1185.08
2026-07-13	UBS	Target Raised	1250 → 1425	1189.91003
2026-07-13	Guggenheim	Target Raised	— → 1273	1188.58
2026-07-09	UBS	Target Raised	1281 → 1370	1222.125
2026-07-08	Truist Financial	Target Raised	— → 1370	1227.07
2026-07-08	RBC Capital	Target Raised	1250 → 1500	1229.21997
2026-07-08	Morgan Stanley	Target Raised	1344 → 1347	1235.56
2026-07-06	Cantor Fitzgerald	Target Raised	— → 1350	1210.5
2026-06-25	Leerink Partners	Target Raised	1119 → 1232	1117.26
2026-06-22	Berenberg Bank	Target Raised	1050 → 1135	1111.67
2026-06-09	Jefferies	Target Raised	1330 → 1350	1143.35
2026-05-26	HSBC	Target Raised	— → 1251	1065
2026-05-26	Leerink Partners	Update	— → 1119	1065
2026-05-21	Wolfe Research	Target Raised	1325 → 1350	1037.82007
2026-05-05	Barclays	Target Raised	1350 → 1400	967.93
2026-05-01	Morgan Stanley	Target Raised	1327 → 1344	961.555
2026-05-01	Cantor Fitzgerald	Target Raised	1205 → 1230	970.675
2026-04-10	Morgan Stanley	Target Raised	1313 → 1327	939.31
2026-03-13	Jefferies	Update	— → 1300	1000.78003
2026-03-06	Deutsche Bank	Update	— → 1285	990.31
2026-03-05	Morgan Stanley	Update	— → 1313	972.5

News Page 1 of 5

Novartis Faces Setback in Cardiovascular Drug Trial, Impacting Market Outlook for Lp(a) Treatments

09/07/2026, 10:36 PM business review healthcare pharma Ionis Pharmaceuticals Amgen Novartis Eli Lilly

Novartis' recent failure in a key cardiovascular trial for its cholesterol drug pelacarsen has raised concerns about the viability of treatments targeting Lp(a), a cholesterol variant linked to increased heart disease risk, impacting not only Novartis but also its competitors Amgen and Eli Lilly.

Trump to Announce New Drug Pricing Deals with Multiple Pharmaceutical Companies

08/31/2026, 10:37 AM business announcement healthcare Novo Nordisk Pfizer Eli Lilly

President Trump is expected to announce new voluntary drug pricing deals with nearly a dozen pharmaceutical companies, aimed at reducing medication costs in the U.S. by aligning them with lower prices abroad, which could significantly impact the healthcare sector ahead of the midterm elections.

Analysts downgrade PG&E (PCG) and Edison International (EIX) following California lawmakers' decision on wildfire liability limits

08/31/2026, 10:37 AM business rating_drop Analysts Science Applications International Howmet Aerospace Edison International PG&E Corporation GameStop Apple Eli Lilly

California lawmakers' decision to block a proposal limiting wildfire liability for utility companies has led to significant stock declines for PG&E and Edison International, while other companies like Science Applications International and GameStop saw positive movements due to earnings forecasts and preliminary results.

Novo Nordisk CEO Mike Doustdar Defends Lawsuit Against Eli Lilly Over Weight-Loss Drug Advertising

08/12/2026, 04:36 PM business announcement Novo Nordisk Eli Lilly

Novo Nordisk's CEO Mike Doustdar has publicly defended the company's lawsuit against Eli Lilly, claiming that Lilly's advertising misrepresents the efficacy of its weight-loss drug Zepbound compared to Novo's Wegovy. This legal dispute highlights the intensifying competition in the GLP-1 market, which could impact market shares and investor sentiment.

Eli Lilly Files Six Lawsuits Against Companies for Illegal Sales of Experimental Obesity Drug Retatrutide

08/12/2026, 04:36 AM announcement Eli Lilly

Eli Lilly has initiated six lawsuits against various U.S. companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide, which is still undergoing clinical trials. This move highlights the company's efforts to combat the illegal market for unapproved drugs and protect consumer safety.

Eli Lilly Secures First International Approval for Weight-Loss Drug Foundayo, Competing with Novo Nordisk’s Wegovy in the U.K.

08/11/2026, 02:37 AM business announcement healthcare Novo Nordisk Eli Lilly

Eli Lilly's weight-loss drug Foundayo has received its first approval for sale in the U.K., positioning it to compete directly with Novo Nordisk's Wegovy pill. This approval is significant as it introduces a second GLP-1 weight-loss option in Europe, potentially expanding the market for oral weight-loss medications.

Trivector Research Recommends Investing in 'Non-Tech Compounders' for Strong Returns Beyond AI

08/10/2026, 12:39 PM investing research healthcare consumer Tapestry Parker Hannifin Eli Lilly

Investors are encouraged to consider 'non-tech compounders' as a strategy to diversify portfolios amid market volatility driven by AI and semiconductor stocks. Trivector Research identifies these companies as having strong growth potential without the risks associated with crowded trades in the tech sector.

Eli Lilly Outperforms Novo Nordisk as Market Confidence Diverges Following Earnings Reports

08/06/2026, 07:41 AM business review healthcare Novo Nordisk Eli Lilly

Eli Lilly and Novo Nordisk reported strong second-quarter earnings, but investor reactions diverged significantly, highlighting a growing confidence gap between the two companies in the competitive obesity drug market.

Stocks Making Significant Moves Premarket: SpaceX, AMD, Eli Lilly, and Disney Report Mixed Results

08/05/2026, 05:37 AM business review Pixar Animation Studios Advanced Micro Devices SpaceX DaVita Wynn Resorts Arista Networks CVS Health Pinterest Eli Lilly

Premarket trading saw significant movements among several major companies, with SpaceX experiencing a notable decline following its quarterly report, while Eli Lilly and Arista Networks reported strong earnings that boosted their stock prices. These fluctuations reflect varying investor sentiments based on earnings performance and future guidance.

Eli Lilly (LLY) Reports Strong Q2 Earnings, Raises Full-Year Revenue Outlook Amid Surge in Zepbound and Mounjaro Sales

08/05/2026, 04:38 AM business forecast healthcare Eli Lilly

Eli Lilly's strong second-quarter earnings and revenue, driven by robust sales of its weight loss and diabetes drugs, have led the company to raise its full-year revenue outlook significantly, indicating strong market demand and growth potential.